RAPP Q3 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$18M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$331M

Total Liabilities

$8M

Stockholders' Equity

$323M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$22M	-$10M	-126.3%
Net Income	-$18M	-$9M	-101.4%